Related Experiment Video
Updated: Jan 19, 2026
Insulin: The Receptor and Signaling Pathways
GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery
Manveen K Gupta1, Neelakantan T Vasudevan2
1Department of Molecular Cardiology, Cleveland Clinic, Cleveland, Ohio 44106, United States.
Abstract:
Type 2 diabetes is a major health issue worldwide with complex metabolic and endocrine abnormalities. Hyperglycemia, defects in insulin secretion and insulin resistance are classic features of type 2 diabetes. Insulin signaling regulates metabolic homeostasis by regulating glucose and lipid turnover in the liver, skeletal muscle and adipose tissue. Major treatment modalities for diabetes include the drugs from the class of sulfonyl urea, Insulin, GLP-1 agonists, SGLT2 inhibitors, DPP-IV inhibitors and Thiazolidinediones. Emerging antidiabetic therapeutics also include classes of drugs targeting GPCRs in the liver, adipose tissue and skeletal muscle. Interestingly, recent research highlights several shared intermediates between insulin and GPCR signaling cascades opening potential novel avenues for diabetic drug discovery.
More Related Videos
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
10:13Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Drug Discovery: Overview
08:45Epigenetic Conversion as a Safe and Simple Method to Obtain Insulin-secreting Cells from Adult Skin Fibroblasts
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

